UPPSALA, SWEDEN – LIDDS publicerar idag årsredovisningen för verksamhetsåret 2019
Årsredovisningen återfinns på bolagets hemsida, se https://liddspharma.com/investors/#financial-reports.
För mer information, vänligen kontakta:
Monica Wallter, CEO, LIDDS +46 (0)737 07 09 22 monica.wallter@liddspharma.com
Informationen lämnades för publicering 22 april 2020, kl 16:00.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.
Bilaga
